Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition
01 déc. 2017 07h00 HE
|
Curis, Inc.
LEXINGTON, Mass., Dec. 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Curis Reports Third Quarter 2017 Financial Results
07 nov. 2017 07h00 HE
|
Curis, Inc.
LEXINGTON, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis to Present at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit
03 nov. 2017 07h00 HE
|
Curis, Inc.
LEXINGTON, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Curis to Release Third Quarter 2017 Financial Results and Hold Conference Call on November 7, 2017
01 nov. 2017 07h00 HE
|
Curis, Inc.
LEXINGTON, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis to Present at the Cantor Fitzgerald Global Healthcare Conference
22 sept. 2017 11h54 HE
|
Curis, Inc
LEXINGTON, Mass., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Curis Announces Pricing of Public Offering of Common Stock
14 sept. 2017 07h00 HE
|
Curis, Inc
LEXINGTON, Mass., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company, today announced the pricing of an underwritten public offering of 20,000,000 shares of its...
Curis Announces Proposed Public Offering of Common Stock
13 sept. 2017 16h04 HE
|
Curis, Inc
LEXINGTON, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company, today announced its intention to offer and sell up to 20 million shares of its common stock...
Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017
11 sept. 2017 04h00 HE
|
Curis, Inc
-- Results from 34 Patients Demonstrate Positive Safety Profile and Support Decision to Expand Development -- -- Aurigene and Curis Plan Clinical Trial of CA-170 in India -- LEXINGTON, Mass., Sept. ...
Curis to Present at the Baird 2017 Global Healthcare Conference
06 sept. 2017 07h00 HE
|
Curis, Inc
LEXINGTON, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress
31 août 2017 07h00 HE
|
Curis, Inc
LEXINGTON, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...